New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
07:05 EDTBSX, BAYRYBoston Scientific agrees to acquire Interventional division of Bayer for $415M
Boston Scientific (BSX) has entered into a definitive agreement to acquire the Interventional Division of Bayer AG (BAYRY) for $415M in cash, including fees for transitional services. The company expects to close the transaction in the second half of 2014, subject to customary closing conditions. The acquisition is expected to improve Boston Scientific's access to a number of attractive segments in the peripheral space, including the growing atherectomy and thrombectomy categories. In 2013, Bayer Interventional generated sales of approximately $120M. Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific Peripheral Interventions business. The agreement calls for an up-front payment of $415M. The company currently expects the transaction to be immaterial to adjusted earnings per share in 2014, accretive by approximately 1c in 2015 and increasingly accretive thereafter. On a GAAP earnings per share basis, the company expects the transaction to be slightly dilutive in 2014, immaterial in 2015, and less accretive than on an adjusted earnings per share basis thereafter as a result of acquisition-related net charges and amortization, which will be determined following the closing. Closing of the transaction is subject to customary conditions, including relevant antitrust clearance, and is expected to occur in the second half of 2014.
News For BSX;BAYRY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
11:34 EDTBAYRYMerck completes sale of Consumer Care business to Bayer $14.2B
Merck (MRK) said it has completed the previously announced sale of the Merck Consumer Care business to Bayer (BAYRY). Bayer will acquire Merck’s existing over-the-counter business, including the global trademark and prescription rights for CLARITINTM and AFRINTM, for $14.2B or approximately $9B in after-tax proceeds, less customary closing adjustments as well as certain contingent amounts held back that will be payable upon the manufacturing site transfer in Canada and regulatory approvals in Mexico and Korea. In conjunction with this transaction, Merck has also entered into the previously announced worldwide collaboration between the companies to develop and commercialize soluble guanylate cyclase modulators. This collaboration includes Bayer’s ADEMPASTM. The collaboration also includes opt-in rights for other early-stage sGC compounds in development by both companies. Merck will be making an upfront payment of $1B in connection with the sGC collaboration.
September 30, 2014
12:12 EDTBAYRYOncoMed cancer pipeline expanded with new candidate, says Piper Jaffray
Subscribe for More Information
10:02 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:37 EDTBAYRYOncoMed announces advancement small molecule Wnt pathway inhibitor
Subscribe for More Information
06:56 EDTBSXBoston Scientific initiated with a Hold at Needham
September 25, 2014
11:25 EDTBAYRYBayer said to not plan spin-off of Agrochem unit, Bloomberg reports
Subscribe for More Information
September 24, 2014
16:41 EDTBSXCourt says Boston Scientific breached license agreement
Boston Scientific disclosed in a regulatory filing that on September 24, following a jury verdict against Boston Scientific Corporation, the Montgomery County Circuit Court in Maryland entered a judgment that the company breached its license agreement with Mirowski Family Ventures and awarded damages of $308M. The company believes the facts and the law do not support the jury’s findings or the amount of the damages. The company plans to seek to overturn the judgment in post-trial motions with the Circuit Court and, if necessary, through the appeals process.
September 23, 2014
16:09 EDTBSXBoston Scientific enrolls first patients in U.S. trial of Lotus Valve System
Boston Scientific has initiated the REPRISE III clinical trial, a pivotal study to evaluate the safety and effectiveness of the Lotus Valve System in patients with severe aortic stenosis and who are considered to be at either high or extreme risk for surgical valve replacement. The Lotus Valve System is the first transcatheter aortic valve replacement device that is both fully repositionable and retrievable prior to release. The primary endpoints of the study are Safety; composite of all-cause mortality, stroke, life-threatening and major bleeding events, stage two or three acute kidney injury or major vascular complications at 30 days. Efficacy; composite of all-cause mortality, disabling stroke or moderate or greater paravalvular aortic regurgitation at one year following procedure.
09:00 EDTBAYRYBofa/Merill special situations team to hold an analyst/industry conference call
Subscribe for More Information
September 22, 2014
05:17 EDTBAYRYRegeneron announces EYLEA injection approved for myopic CNV treatment in Japan
Subscribe for More Information
September 19, 2014
07:35 EDTBAYRYZoetis seen as potential Bayer target after split announcement, Bloomberg says
Subscribe for More Information
September 18, 2014
06:20 EDTBAYRYBayer to float MaterialScience as separate company
Subscribe for More Information
September 17, 2014
17:44 EDTBAYRYBayer plans separation of MaterialsSciences unit, WSJ says
Subscribe for More Information
07:43 EDTBSXBofA/Merrill to hold a conference
Subscribe for More Information
05:09 EDTBSXBoston Scientific receives CE Mark for Vercise DBS system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use